## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr
A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol
✍ Scribed by George A. Kenna; Lorenzo Leggio; Robert M. Swift
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 94 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.1042
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
There are no reports examining the safety of taking both topiramate and aripiprazole together with alcohol. The ultimate aim for this research is to determine whether this combination is safe and is superior to either drug taken alone in reducing alcohol use in alcohol dependent patients.
Method
This was an open‐label trial. Thirteen heavy drinking participants not seeking treatment for alcoholism were randomized. Participants were titrated up to 300 mg of topiramate and 30 mg of aripiprazole a day over 35 days. Participants reported adverse events (AEs) daily alcohol use and participated in an alcohol challenge session (ACS).
Results
The eight participants who completed the study achieved the maximum doses of drugs. The AEs of the drugs would suggest that the AEs profile is broader but not additive. Alcohol use from the 28 days before screening to the seven days before the ACS was reduced (p = 0.08).
Conclusion
There was no evidence that AEs of aripiprazole and topiramate are additive and can, therefore, be administered safely together with a modest amount of alcohol. There was also a trend for a reduction of alcohol use by participants. This finding has implications for further investigation of this combination of drugs for alcohol dependence. Copyright © 2009 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Tolcapone is a potent, reversible catechol‐O‐methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve motor function and allow levodopa dose reductions in Parkinson's disease (PD) patients who are experiencing either a stable resp
## BACKGROUND. Chemotherapy-induced emesis is one of the most disturbing side effects of cancer therapy. Control of acute emesis has improved substantially during recent years, but control of delayed emesis and nausea remains a challenging problem. The role of 5-HT3 receptor antagonists in the tre
## Abstract Gallbladder cancer is a rare cancer with a poor prognosis, and few risk factors have been identified to date. This prospective study was conducted to evaluate the association of cigarette smoking and alcohol consumption with the risk of gallbladder cancer death. A baseline survey in 45
## Abstract The present investigation is designed to work out the isolated and in‐combination effects of Zn^2+^, Cr^6+^ and Ni^2+^ to a fish __Mystus vittatus__. From all the 12 combinations, 6 are antagonistic and 6 are synergistic. The combination Cr/Ni is highly synergistic while combination (